-
-
-
Global experts in nanotechnology and drug particle engineering
Our latest videos
Press releases
-
Regulatory January 3, 2022Nanoform sets two new near-term business targets for 2022
-
Regulatory December 10, 2021Nanoform financial calendar for 2022
-
Regulatory November 25, 2021Nanoform Interim Report January – September 2021
Nanoform Finland Plc, published it’s Interim Report January – September 2021 on November 25th, 2021 at 08.10 a.m. Finnish time.
a
Nanoform is an innovative nanoparticle medicine enabling company that supplies best in class nanoforming services. Our multi-patented CESS® technology can double the amount of lead compounds progressing into clinic, leading to a significant increase in the number of drugs that reach the market. The green particle engineering process produces pure and stable nanoparticles as small as 10 nm using supercritical carbon dioxide.
About Nanoform
Our work enables our partners to overcome drug development challenges to rapidly progress novel drugs to market. We are driven by a passion for innovation, and constantly work to find ground-breaking solutions that enhance drug effectiveness and targeting.
Expert services
Our nanoforming services provide solutions to complex formulation challenges by increasing drug solubility and bioavailability. The advanced production of nanoparticles provides pharmacokinetic improvements, commercial opportunities and novel avenues for drug delivery.
Team
We have established a multidisciplinary team that brings together world-class scientists with experts in pharmaceutical business development. Every member of the team is committed to the enhancement of drug compounds for swift progression to the market.
Working together for enhanced drug development
We work with our partners to successfully nanoformTM APIs for a range of therapeutic areas. Together, we can develop life changing medicines that will reach patients across the globe.
Nanoform’s platform is exciting for its broad applicability to drug development across all therapeutic areas
